

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-15 (cancelled).

16. (new) A method of use of type 1 Placental Growth Factor (PLGF-1) comprising preparing a medicament that comprises PLGF-1 as an active principle, wherein said medicament promotes angiogenesis in the treatment of a state selected from the group consisting of:

- diseases and pathological alterations involving the cutaneous or subcutaneous connective tissue,
- scleroderma, and
- early skin ageing due to exposure to atmospheric aggressive agents or to protracted solar irradiation.

17. (new) The method of use according to claim 16, wherein the state is selected from the group consisting of localized scleroderma and progressive systemic scleroderma.

18. (new) The method of use according to claim 17, wherein the localized scleroderma is cutaneous scleroderma and the progressive systemic scleroderma is myocardial scleroderma.

19. (new) The method of use according to claim 16, for treatment of a pathological loss of hair due to a state selected from the group consisting of alopecia, hormonal disorders, chemotherapy, radiotherapy and administration of medicine.

20. (new) The method of use according to claim 16, wherein the medicament is in a form suitable for generating a local or systemic effect.
21. (new) The method of use according to claim 16, wherein the medicament is in a form suitable for endovenous, intramuscular, intrarticular, subcutaneous or topical administration or subcutaneous implant or ionophoresis.
22. (new) The method of use according to claim 19, wherein the medicament is in a form suitable for endovenous, intramuscular, intrarticular, subcutaneous or topical administration or subcutaneous implant or ionophoresis.
23. (new) A method of use of type 1 Placental Growth Factor (PLGF-1) comprising administering PLGF-1 to promote cutaneous or subcutaneous angiogenesis in the prevention and cosmetic treatment of natural skin ageing.
24. (new) A method of use of type 1 Placental Growth Factor (PLGF-1) comprising administering PLGF-1 to promote perifollicular angiogenesis in the prevention and in the cosmetic treatment of the natural loss of hair.
25. (new) The method of use according to claim 23, wherein the PLGF-1 is formulated in a cosmetic composition for topical administration.
26. (new) The method of use according to claim 24, wherein the PLGF-1 is formulated in a cosmetic composition for topical administration.
27. (new) The method of use according to claim 16, wherein PLGF-1 is comprised in an amount suitable for an administration of 1 to 500 μg per Kg of body per day, preferably of 10 $\mu\text{g/Kg/day}$ to 200 $\mu\text{g/Kg/day}$.

28. (new) The method of use according to claim 23, wherein PLGF-1 is comprised in an amount suitable for an administration of 1 to 500 µg per Kg of body per day, preferably of 10 µg/Kg/day to 200 µg/Kg/day.

29. (new) The method of use according to claim 24, wherein PLGF-1 is comprised in an amount suitable for an administration of 1 to 500 µg per Kg of body per day, preferably of 10 µg/Kg/day to 200 µg/Kg/day.

30. (new) A pharmaceutical composition comprising PLGF-1 as active principle and a pharmaceutically acceptable excipient, wherein at least 98.5% of the PLGF-1 is in active dimeric and multimeric form, at least 70% is in dimeric form and no more than 1.5% is in monomeric form, and wherein PLGF-1 is comprised in an amount from 50 µg to 30 mg per unitary dose for parenteral use and in an amount from 0.1 mg to 10 mg per gram of composition for topical use.

31. (new) A cosmetic composition comprising PLGF-1 as active principle and a cosmetically acceptable excipient, wherein at least 98.5% of the PLGF-1 is in active dimeric and multimeric form, at least 70% is in dimeric form and no more than 1.5% is in monomeric form, and wherein PLGF-1 is comprised in an amount from 0.01 mg to 0.09 mg per gram of composition.

32. (new) The composition according to claim 30, in a form selected from the group consisting of a solution, a lotion, a W/O emulsion, an O/W emulsion, a suspension, a liposome suspension, a gel, a cream, a paste, an ointment and a subcutaneous implant.

33. (new) The composition according to claim 31, in a form selected from the group consisting of a solution, a lotion, a W/O emulsion, an O/W emulsion, a suspension, a liposome suspension, a gel, a cream, a paste, an ointment and a subcutaneous implant.

34. (new) The composition according to claim 30, additionally comprising one or more substances capable of stabilizing the PLGF-1 in the active dimeric-multimeric forms.

35. (new) The composition according to claim 31, additionally comprising one or more substances capable of stabilising the PLGF-1 in the active dimeric-multimeric forms.